Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SK-BR-3 Cisplatin
1.0
Chemo
Chemotherapy
 0.9143 -0.00500
MDA-MB-453 Bleomycin
0.0010833
Radiation
Misc
 1.0703 -0.00500
CAL-120 Ipatasertib
0.031623
AKT
PI3K/mTOR
 0.9413 -0.00498
HCC1806 Cisplatin
0.0033333
Chemo
Chemotherapy
 1.0548 -0.00497
SK-BR-3 A-1210477
0.0031623
Mcl-1
Misc
 0.9516 -0.00496
CAL-120 Ipatasertib
1.0
AKT
PI3K/mTOR
 0.7753 -0.00495
SK-BR-3 ABT-737
1.0
Bcl2/XL
Misc
 1.0019 -0.00495
HCC1428 Cediranib
0.001
VEGFR/cKIT
RTK
 1.1400 -0.00495
PDX1328 Pictilisib
0.0031623
pan PI3K
PI3K/mTOR
 1.1879 -0.00495
HCC1500 Ipatasertib
1.0
AKT
PI3K/mTOR
 0.9536 -0.00494
HCC1143 AZD7762
0.001
CHK1/2
Cell cycle
 1.1696 -0.00494
HCC1419 Etoposide
0.31623
Topo II
Chemotherapy
 0.8518 -0.00493
PDXHCI002 Cediranib
0.001
VEGFR/cKIT
RTK
 1.0840 -0.00493
MDA-MB-157 INK-128
0.0031623
mTORC1/2
PI3K/mTOR
 0.8813 -0.00492
CAMA-1 Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
 1.0346 -0.00490
SUM1315MO2 Etoposide
0.0033333
Topo II
Chemotherapy
 0.9789 -0.00489
HCC1419 Vorinostat
0.01
HDAC
Misc
 0.9913 -0.00489
CAMA-1 Trametinib
0.0031623
MEK
MAPK/nRTK
 0.9489 -0.00489
CAL-85-1 TGX221
0.0031623
PI3Kb
PI3K/mTOR
 1.0531 -0.00488
HCC1428 Abemaciclib
0.001
CDK4/6
Cell cycle
 0.9431 -0.00488
SUM1315MO2 TGX221
0.0031623
PI3Kb
PI3K/mTOR
 0.9766 -0.00487
CAL-120 Everolimus
0.0031623
mTOR1
PI3K/mTOR
 0.6255 -0.00487
CAMA-1 Pictilisib
0.001
pan PI3K
PI3K/mTOR
 0.9447 -0.00486
HCC1419 Cabozantinib
3.1623
VEGFR2/MET
RTK
 1.0922 -0.00486
SK-BR-3 Ipatasertib
0.0031623
AKT
PI3K/mTOR
 1.0766 -0.00484